871115-65-0

Basic information

• Product Name: 3-aMino-1-Methyl-3-PyrrolidineMethanaMine
• Synonyms: 3-aMino-1-Methyl-3-PyrrolidineMethanaMine
• CAS NO: 871115-65-0
• Molecular Formula: C6H15N3
• Molecular Weight: 129.2034
• Mol File: 871115-65-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-aMino-1-Methyl-3-PyrrolidineMethanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-aMino-1-Methyl-3-PyrrolidineMethanaMine(871115-65-0)
• EPA Substance Registry System: 3-aMino-1-Methyl-3-PyrrolidineMethanaMine(871115-65-0)

Safety Data

• Hazardous Substances Data: 871115-65-0(Hazardous Substances Data)

Upstream product

• 934372-75-5 2,2,2-trifluoro-N-{1-methyl-3-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidin-3-yl}-acetamide 
• 871115-54-7 tert-butyl 3-amino-3-cyanopyrrolidine-1-carboxylate 
• 871115-55-8 3-cyano-3-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 871115-56-9 3-aminomethyl-3-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 871115-57-0 3-(2,2,2-trifluoro-acetylamino)-3-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 871115-64-9 N-(3-aminomethyl-1-methyl-pyrrolidin-3-yl)-2,2,2-trifluoro-acetamide 

Relevant articles and documents

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series exhibit lower MICs than rifabutin against rifampin-resistant strains of S. aureus. Further, compound 2e exhibits comparable efficacy in vivo in a murine model of S. aureus septicemia model following administration by either oral or parenteral dosing routes.

Spiro-rifamycin derivatives targeting RNA polymerase

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.